CJC-1295 DAC — Research Summary
CJC-1295 DAC is a modified growth hormone releasing hormone (GHRH) analogue peptide designed for advanced research applications. This formulation incorporates a Drug Affinity Complex (DAC) component that significantly extends the peptide’s half-life compared to standard CJC-1295 variants. Researchers at Stroid UK Shop investigate this compound for its sustained bioactivity profile and prolonged receptor binding characteristics in preclinical models. The DAC modification enables researchers to examine extended-release kinetics and reduced dosing frequency requirements in experimental protocols.
Laboratory Applications
Research scientists examine CJC-1295 DAC for its interaction with GHRH receptors and subsequent growth hormone axis modulation in controlled laboratory settings. The peptide’s enhanced pharmacokinetic profile makes it particularly valuable for studies requiring sustained receptor engagement over extended timeframes. Investigators studying peptides analyse this compound’s effects on pulsatile hormone release patterns and circadian rhythm interactions. The DAC component allows researchers to evaluate once-weekly administration protocols versus traditional multiple-daily dosing regimens. Studies focus on growth factor signalling pathways, IGF-1 expression modulation, and downstream metabolic cascades in tissue culture and animal models.
Technical Specifications
| Parameter | Value |
|---|---|
| Molecular Weight | 3647.28 g/mol (with DAC) |
| Purity | ≥98% (HPLC verified) |
| Form | Lyophilised powder |
| Storage | -20°C protected from light |
| Solubility | Water, bacteriostatic water |
| Research Half-life | 6-8 days (with DAC) |
Researchers studying CJC-1295 peptide compounds compare this DAC variant against standard formulations to evaluate sustained-release characteristics. The extended half-life enables investigation of weekly administration protocols in research models. Laboratory personnel examine reconstitution stability and maintain proper cold-chain storage protocols throughout experimental procedures. Research teams also investigate this compound alongside SARMs in combination studies examining synergistic pathways in growth factor research.
Compliance Statement
This CJC-1295 DAC 5mg formulation is supplied strictly for in-vitro laboratory research purposes only. This peptide compound is not intended for human consumption, clinical application, or therapeutic use. Researchers must maintain appropriate laboratory protocols and safety procedures when handling this research chemical. All experimental work should be conducted in controlled laboratory environments by qualified research personnel only.
